Appointment of Joint Broker28th March 2018 - 11:55 am
ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corporate broker to act alongside Northland Capital Partners who remain the Company’s Nominated Adviser and joint corporate broker.
Tim McCarthy, Chairman of Immupharma, commented: “We welcome Bryan Garnier as Joint Broker. Bryan Garnier provides Immupharma with deep healthcare expertise and pan European broking capability, to support the Company as we progress towards commercialisation.”
Olivier Garnier, Founder and Managing Partner of Bryan, Garnier & Co. commented: “We are delighted to be appointed and we look forward to working with the Company at this very exciting time.”